| abstract |
Schizophrenia is a serious disease affecting one percent of the entire global population. Even though the detrimental effects of Schizophrenia on the individual and society at large are known and well documented, it is commonly agreed in the medical community that one of the main unmet needs in the treatment of Schizophrenia is a composition which can treat cognition impairment while also preventing or treating Schizophrenia-triggered psychosis. The present invention provides compositions and agents for addressing this unmet need. In particular, the agents are 5-HT3R and/or 5-HT6R antagonists. |